Evaluating a New Blood Test for Early Cancer Detection in People with Hereditary Cancer Syndromes A Study Comparing Standard Care and cfDNA Testing for Earlier Cancer Diagnosis and Impact on Patient Well-being

What this Trial Is About

Researchers are studying an experimental blood test that detects early tumors in patients with hereditary cancer syndromes. This test, called cell-free DNA cfDNA analysis, aims to improve cancer screening by identifying cancer sooner than standard methods. The study compares cancer detection rates and timing between patients receiving cfDNA testing and those receiving regular care, while also exploring the impact on patients quality of life and psychological well-being. Participants are divided into two groups the experimental group provides blood samples every four months for four years for cfDNA testing, with results given back to them. Those with positive results will be offered follow-up tests to confirm cancer presence. The control group continues with their usual cancer surveillance without cfDNA testing. Both groups complete questionnaires and interviews to share their experiences and views on the blood test. During the study, participants attend regular blood sample collections, often coordinated with routine clinical blood draws to reduce extra procedures. Researchers measure cancer detection rates over four years and assess if cfDNA testing leads to earlier cancer diagnosis. They also evaluate participants cancer-related worry, anxiety, and quality of life. The study lasts for four years, with ongoing monitoring and support to understand the tests clinical and personal impact.

CfDNA in Hereditary And High-risk Malignancies 2